secwatch / observer
8-K filed September 22, 2025, 7:59 PM ET ticker CYTK CIK 0001061983
debt confidence high sentiment neutral materiality 0.75

Cytokinetics issues $750M 1.75% convertible notes; refinances $399.5M of 2027 notes

CYTOKINETICS INC

item 1.01item 2.03item 3.02item 8.01item 9.01

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001193125-25-209437
form_type
8-K
ticker
CYTK
cik
0001061983
company_name
CYTOKINETICS INC
filed_at
2025-09-22T23:59:59+00:00
discovered_at
2026-05-14T18:02:43.229708+00:00
generated_at
2026-05-17T05:56:30.942799+00:00
sec_items
["1.01", "2.03", "3.02", "8.01", "9.01"]
event_type
debt
sentiment
neutral
materiality_score
0.75
calibrated_materiality_score
0.75
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001193125-25-209437
json_url
https://secwatch.observer/filing/0001193125-25-209437.json
markdown_url
https://secwatch.observer/filing/0001193125-25-209437.md
text_url
https://secwatch.observer/filing/0001193125-25-209437.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/1061983/000119312525209437/0001193125-25-209437-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/1061983/000119312525209437/d933506d8k.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null
JSON Markdown Plain text

Source-grounded claims

c7e8634a8101251c9b2108d05403ac6d43207daf

CYTOKINETICS INC incurred convertible notes of $750.0 million aggregate principal amount with initial purchasers at 1.75% per year maturing October 1, 2031.

On September 19, 2025, Cytokinetics, Incorporated (the “Company”) issued $750.0 million aggregate principal amount of its 1.75% Convertible Senior Notes due 2031 (the “Notes”), which includes the full exercise of the initial purchasers’ option to purchase up to an additional $100.0 million aggregate principal amount of Notes.

SEC 8-K Item 2.03/2.04 confidence 0.98 SEC evidence

Comparable filings

KNX

Knight-Swift closes $1.5B convertible note offering at 1.00% due 2031; proceeds used to repay term loans and revolver

Knight-Swift Transportation Holdings Inc. May 8, 2026, 7:59 PM ET debt Items 1.01, 2.03, 3.02, 8.01, 9.01

same fact type: debt_financing same SEC item: 1.01, 2.03, 3.02, 8.01, 9.01 same event type: debt similar materiality

This filing

On September 19, 2025, Cytokinetics, Incorporated (the “Company”) issued $750.0 million aggregate principal amount of its 1.75% Convertible Senior Notes due 2031 (the “Notes”), which includes the full exercise of the initial purchasers’ option to purchase up to an additional $100.0 million aggregate principal amount of Notes.

Comparable filing

On May 8, 2026, Knight-Swift Transportation Holdings Inc. (the "Company") completed its previously announced private offering (the "Offering") of $1.5 billion aggregate principal amount of 1.00% Convertible Senior Notes due 2031

Filing page SEC filing

PUMP

ProPetro issues $690M zero-coupon convertible notes due 2031, expands credit facility

ProPetro Holding Corp. May 7, 2026, 7:59 PM ET debt Items 1.01, 2.03, 3.02, 8.01, 9.01

same fact type: debt_financing same SEC item: 1.01, 2.03, 3.02, 8.01, 9.01 same event type: debt similar materiality

This filing

On September 19, 2025, Cytokinetics, Incorporated (the “Company”) issued $750.0 million aggregate principal amount of its 1.75% Convertible Senior Notes due 2031 (the “Notes”), which includes the full exercise of the initial purchasers’ option to purchase up to an additional $100.0 million aggregate principal amount of Notes.

Comparable filing

On May 7, 2026, ProPetro Holding Corp. (the “ Company ”), issued $690 million aggregate principal amount of its 0.00% Convertible Senior Notes due 2031

Filing page SEC filing

RENX

RenX Enterprises raises up to $100M via tranched convertible note and warrant private placement

RenX Enterprises Corp. May 5, 2026, 7:59 PM ET debt Items 1.01, 2.03, 3.02, 7.01, 8.01, 9.01

same fact type: debt_financing same SEC item: 1.01, 2.03, 3.02, 8.01, 9.01 same event type: debt similar materiality

This filing

On September 19, 2025, Cytokinetics, Incorporated (the “Company”) issued $750.0 million aggregate principal amount of its 1.75% Convertible Senior Notes due 2031 (the “Notes”), which includes the full exercise of the initial purchasers’ option to purchase up to an additional $100.0 million aggregate principal amount of Notes.

Comparable filing

Purchase Agreement, the Company (i) issued and sold to the Purchasers, at the initial closing on May 4, 2026 (the “Initial Closing”), Notes in the aggregate principal amount of $6,300,000 (the “Initial Notes”) and warrants (the “Initial Warrants”) to purchase an aggregate of 3,917,099 shares of Common Stock (which is equal to 180% of the face value of the Initial

Filing page SEC filing

BRLS

Borealis Foods enters $17M term loan with Oxus, repays Frontwell; potential equity conversion up to $33.3M

Borealis Foods Inc. May 1, 2026, 7:59 PM ET debt Items 1.01, 1.02, 2.03, 3.02, 5.02, 8.01, 9.01

same fact type: debt_financing same SEC item: 1.01, 2.03, 3.02, 8.01, 9.01 same event type: debt similar materiality

This filing

On September 19, 2025, Cytokinetics, Incorporated (the “Company”) issued $750.0 million aggregate principal amount of its 1.75% Convertible Senior Notes due 2031 (the “Notes”), which includes the full exercise of the initial purchasers’ option to purchase up to an additional $100.0 million aggregate principal amount of Notes.

Comparable filing

SPAC sponsor and a significant shareholder of the Company. Pursuant to the Credit Agreement, Oxus provided a term loan to the Borrowers in an aggregate principal amount of up to $17.0 million (the “Term Loan”). The obligations under the Credit Agreement are guaranteed by the Company, Borealis IP Inc., and Palmetto Gourmet Foods (Canada) Inc. (collectively, the

Filing page SEC filing

EMAT

EMAT secures $100M convertible debenture facility from Yorkville; first $20M tranche issued

Evolution Metals & Technologies Corp. May 11, 2026, 7:59 PM ET debt Items 1.01, 2.03, 3.02, 7.01, 9.01

same fact type: debt_financing same SEC item: 1.01, 2.03, 3.02, 9.01 same event type: debt similar materiality

This filing

On September 19, 2025, Cytokinetics, Incorporated (the “Company”) issued $750.0 million aggregate principal amount of its 1.75% Convertible Senior Notes due 2031 (the “Notes”), which includes the full exercise of the initial purchasers’ option to purchase up to an additional $100.0 million aggregate principal amount of Notes.

Comparable filing

The first Convertible Debenture (the “First Debenture”) in the principal amount of $20,000,000 was issued on May 7, 2026.

Filing page SEC filing

TBH

Brag House issues $2.5M convertible notes at 25% OID; proceeds for House of Doge merger

Brag House Holdings, Inc. May 8, 2026, 7:59 PM ET debt Items 1.01, 2.03, 3.02, 9.01

same fact type: debt_financing same SEC item: 1.01, 2.03, 3.02, 9.01 same event type: debt similar materiality

This filing

On September 19, 2025, Cytokinetics, Incorporated (the “Company”) issued $750.0 million aggregate principal amount of its 1.75% Convertible Senior Notes due 2031 (the “Notes”), which includes the full exercise of the initial purchasers’ option to purchase up to an additional $100.0 million aggregate principal amount of Notes.

Comparable filing

The issuance of the Notes in the aggregate original principal amount of $2,500,000 constitutes the creation of a direct financial obligation of the Company. The Notes bear interest at 12.0% per annum, mature on February 4, 2027

Filing page SEC filing

OCGN

Ocugen completes $115M convertible note offering at 6.75%, repays Avenue loan

Ocugen, Inc. May 7, 2026, 7:59 PM ET debt Items 1.01, 1.02, 2.02, 2.03, 3.02, 9.01

same fact type: debt_financing same SEC item: 1.01, 2.03, 3.02, 9.01 same event type: debt similar materiality

This filing

On September 19, 2025, Cytokinetics, Incorporated (the “Company”) issued $750.0 million aggregate principal amount of its 1.75% Convertible Senior Notes due 2031 (the “Notes”), which includes the full exercise of the initial purchasers’ option to purchase up to an additional $100.0 million aggregate principal amount of Notes.

Comparable filing

On May 7, 2026, Ocugen, Inc. (the “Company”) completed its previously announced private offering (the “offering”) of $115.0 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034 (the “notes”).

Filing page SEC filing

HR

HR subsidiary issues $700M 3.00% exchangeable senior notes due 2032

Healthcare Realty Trust Inc May 7, 2026, 7:59 PM ET debt Items 1.01, 2.03, 3.02, 9.01

same fact type: debt_financing same SEC item: 1.01, 2.03, 3.02, 9.01 same event type: debt similar materiality

This filing

On September 19, 2025, Cytokinetics, Incorporated (the “Company”) issued $750.0 million aggregate principal amount of its 1.75% Convertible Senior Notes due 2031 (the “Notes”), which includes the full exercise of the initial purchasers’ option to purchase up to an additional $100.0 million aggregate principal amount of Notes.

Comparable filing

issued $700,000,000 aggregate principal amount of its 3.00% Exchangeable Senior Notes due 2032

Filing page SEC filing

Source: SEC EDGAR
accession 0001193125-25-209437
view filing index on sec.gov
view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.